Skip to main content
. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889

Figure 1.

Figure 1

(A) ACR20, ACR50 and ACR70 sample proportions at week 8, and (B) ACR20, (C) ACR50 and (D) ACR70 responses over time (Fas, NRI). All study treatments were administered once daily. ACR20/50/70, American College of Rheumatology response criteria; Fas, full analysis set; NRI, non-responder imputation.